

August 13, 2022

To,  
Corporate Relations Department  
**BSE Limited,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai-400001.

Security Code: 540788

Security ID: ASPIRA

Sub: Outcome of Board Meeting

Ref: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI Listing Regulations, we wish to inform that, the Board of Directors of the Company in their meeting held today i.e **Saturday, August 13, 2022 (Commenced at 3:30 p.m. and concluded at 4:45 p.m.)**, *inter-alia*, considered and approved: -

- 1) Un-audited Financial Results of the Company for the quarter and three-months ended **June 30, 2022**.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, a copy of the 'Results' along-with Limited Review Report of the Statutory Auditors of the Company, are enclosed herewith.

- 2) Variation/alteration of Preference Shareholders' right by issue and allotment of 55,00,000; 9% Compulsory Convertible Preference Shares ('CCPS') of Rs. 10/- each in lieu of existing 55,00,000, 9% Non-Convertible Non-Cumulative Non-Participating Redeemable Preference Shares (NCRPS) of Rs. 10/- each.

The Board has decided to not to go ahead with this transaction as of now.

- 3) Continuation of Directorship of Dr. Subhash Salunke (DIN: 07940567) as Non-Executive Independent Director subject to the approval of shareholders of the Company. Pursuant to SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015, the disclosure as required is enclosed herewith **Annexure-A**.





## Aspira Pathlab & Diagnostics Limited

**Regd. Office:** Flat No. 2, R D Shah Building, Shraddhanand Road,  
Opp. Railway Station, Ghatkopar (W), Mumbai 400 086  
CIN:L85100MH1973PLC289209

- 4) The 49<sup>th</sup> Annual General Meeting (AGM) for the FY 2021-22, of the Company, will be held on Saturday, September 10, 2022, through Video Conferencing ("VC")/Other Audio Visual Means ("OAVM").
- 5) The Registers of Members and Share Transfer Book of the Company will remain closed from Sunday, September 4, 2022 to Saturday, September 10, 2022 (both days inclusive) for the purpose of 49<sup>th</sup> Annual General Meeting (AGM) to be held on Saturday, September 10, 2022.
- 6) Considered and approved the Director's Report, Management Discussion and Analysis Report and Corporate Governance Report for the year ended March 31, 2022.

The above is for your information and records.

Thanking you,


Yours Faithfully,  
For Aspira Pathlab & Diagnostics Limited



Priya Pandey  
Company Secretary & Compliance Officer  
Encl: As above

**Disclosure of information pursuant to Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015**

Sr. no.	Particulars	Disclosure
1.	Name of Director	Dr. Subhash Salunke (DIN: 07940567)
2.	Reason of Change	Dr. Subhash Salunke aged 74 years, is the Non-Executive, Independent Director of the Company. Dr. Salunke will attain the age of 75 years on April 19, 2023 and pursuant to Regulation 17(1A), the continuation of his Directorship will be subject to approval by the shareholders by way of a special resolution at the 49th Annual General Meeting of the Company.
3.	Date of Appointment / cessation (as applicable)	Continuation of Directorship of Dr. Salunke who will attain the age of 75 years on April 19, 2023.
4.	Term of appointment	Non-Executive, Independent Director
5.	Brief Profile	<p>Dr. Subhash Salunke has been an effective and popular faculty in the subject of Preventive and Social Medicine (Community Medicine) for eight years and a postgraduate guide. Also, he was an adjunct Associate professor of Biological Sciences, human ecology at the University of Texas, USA - School of Public Health - from 1994 to 2000. His 30 years's experience in the Public Health Department spans from Deputy Director to Director General in the Health Services of Maharashtra. Most of his illustrative examples of achievements in contemporary Public Health emanate from his own personal experience. Being an achiever, he has experienced a meteoric rise in the field of Public Health. His stint with the WHO SEARO spanned from being Regional Advisor in 2005 to Assistant Regional Director in 2009, including three years as the WHO representative to Indonesia.</p> <p>He has shown leadership in designing the HIV/AIDS Control special programme (AVERT) with the assistance of USAID for Maharashtra State. He was one of the members of designing National AIDS Control Programme Phase II during 1999-2000 that was a major step in control of HIV/AIDS through the National Programme for Control of HIV/AIDS.</p>
6.	Disclosure of relationships between Directors	He is not related to any other Director or Key Managerial Personnel (KMP) of the Company.





**P KHETAN & CO**  
Chartered Accountants

Office : B-208, Kukreja Centre,  
Plot-13, Sector- 11  
CBD Belapur, Navi Mumbai,  
Mumbai – 400614  
Mobile- 9821376512  
e-mail- [khetanpk@gmail.com](mailto:khetanpk@gmail.com)

**Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to**  
**The Board of Directors**  
**Aspira Pathlab & Diagnostics Limited**

We have reviewed the accompanying statement of **Unaudited Financial Results of Aspira Pathlab & Diagnostics Limited** ("the Company") for the quarter ended June 30, 2022 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI LODR Regulation") including relevant circulars issued by the SEBI from time to time.

The Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the accounting principles laid down in Ind AS 34 prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI LODR Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place- Mumbai  
Date- 13.08.2022

For **P Khetan & Co**  
Chartered Accountant  
Firm Reg. No. 327386E

*Pankaj Khetan*

Pankaj Kumar Khetan  
Partner

Membership No.- 066080  
UDIN: 22066080AOYTTC2925



Aspira Pathlab & Diagnostics Limited

(CIN L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shradhanand Road, Opp. Railway Station, Ghatkopar ( W), Mumbai -400086

Statement of Unaudited Financial Results for the Quarter ended 30th June 2022

(Rs. in Lakhs)

Particulars	Quarter ended			
	30-Jun-22 (Unaudited)	31-Mar-22 (Unaudited) (Refer Note 3)	30-Jun-21 (Unaudited)	31-Mar-22 (Audited)
<b>1. Income</b>				
(a) Revenue from Operations				
Sales/Income from Operations	296.70	543.88	588.39	1,954.19
(b) Other Income	6.49	3.79	2.21	10.29
<b>Total Income</b>	<b>303.19</b>	<b>547.67</b>	<b>590.60</b>	<b>1,964.48</b>
<b>2. Expenses</b>				
(a) Cost of Materials consumed	53.42	81.48	74.88	313.81
(b) Laboratory Testing Charges	10.84	11.79	69.39	119.66
(c) Employee benefits expense	131.81	128.60	114.57	501.95
(d) Finance Costs	10.91	15.30	7.09	37.27
(d) Depreciation and amortisation expense	41.91	51.08	37.76	163.57
(e) Other expenses	82.83	115.15	86.57	382.27
<b>Total Expenses</b>	<b>331.71</b>	<b>403.39</b>	<b>390.26</b>	<b>1,518.53</b>
<b>3. Profit / (Loss) before exceptional items and tax (1-2)</b>	<b>(28.52)</b>	<b>144.28</b>	<b>200.34</b>	<b>445.94</b>
4. Exceptional Items	-	-	-	-
<b>5. Profit / (Loss) before tax (3+4)</b>	<b>(28.52)</b>	<b>144.28</b>	<b>200.34</b>	<b>445.94</b>
6. Tax Expenses	-	-	-	-
<b>7. Profit / (Loss) after tax (5-6)</b>	<b>(28.52)</b>	<b>144.28</b>	<b>200.34</b>	<b>445.94</b>
8. Other Comprehensive income (net of tax)	-	1.55	-	1.55
<b>9. Total Comprehensive income (7+8)</b>	<b>(28.52)</b>	<b>145.83</b>	<b>200.34</b>	<b>447.49</b>
10. Paid up Equity share capital (Face value of Rs. 10/- each)	1,029.30	1,029.30	1,029.30	1,029.30
11. Other equity				249.65
<b>12. Earning per share</b>				
(a) Basic	(0.28)	1.40	1.95	4.33
(b) Diluted	(0.28)	1.40	1.95	4.33

Note

1. The above financial results of the Company were reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meetings held on 13.08.2022. The statutory auditors of the Company have expressed an unmodified opinion thereon.

2. The financial results of the Company have been prepared in accordance with Indian Accounting standards (Ind AS) as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act 2013 read with Companies (Indian Accounting Standard) Rules, 2015, and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India, to the extent applicable.

3. The figures for the quarter ended 31 March 2022 are the balancing figures between audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December 2021 respectively, which was subjected to limited review.

4. The above financial results for the quarter ended 30 June 2022 are not comparable with the financial results for the quarter ended 30 June 2021, due to resurgent wave of COVID-19 during the quarter ended 30 June 2021.

5. The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact after the Code becomes effective.

6. The previous period figures have been regrouped/reclassified wherever required to make them comparable with the figure of the current period.

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Dr. Pankaj J. Shah  
Managing Director

DIN: 02836324

Place: Mumbai

Date: 13.08.2022



For Identification only





## Aspira Pathlab & Diagnostics Limited

Regd. Office: Flat No. 2, R D Shah Building, Shraddhanand Road,  
Opp. Railway Station, Ghatkopar (W), Mumbai 400 086  
CIN:L85100MH1973PLC289209

August 13, 2022

To,  
Corporate Relations Department  
**BSE Limited,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai-400001.

Security Code: 540788

Security ID: ASPIRA

Subject: Intimation of Annual General Meeting (AGM), E-voting period and Book Closure

Dear Sir/Madam,

Pursuant to Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that:

Annual General Meeting Details	<b>Date, Place and Time:</b> Saturday, September 10, 2022 at 11:30 a.m. through Video Conferencing/Other Audio Visual Means Place: Mumbai
E-voting Period	September 7, 2022 (9:00 AM) and ends on September 9, 2022 (5:00 AM)
Cut-off date for E-voting Period	September 3, 2022
Book Closure Period	Sunday, September 4, 2022 to Saturday, September 10, 2022 (both days inclusive)

Kindly note that the Register of Members and Share Transfer Books of the Company will remain closed during above mentioned book closure period.

Request you to Kindly take of the same and disseminate for the information of all the stakeholders.

Thanking you,

Yours Faithfully,  
For Aspira Pathlab & Diagnostics Limited

  
Priya Pandey  
Company Secretary & Compliance Officer



August 13, 2022

To,  
Corporate Relations Department  
**BSE Limited,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai-400001.

Security Code: 540788

Security ID: ASPIRA

Sub: Notice of Book Closure for the purpose of Annual General Meeting of the Company

Dear Sir/Madam,

Pursuant to Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Register of Members and Share Transfer Books of the Company will remain closed during the following period:

Scrip Code, Type of Security & paid-up Value	Book Closure Date	Purpose
540788, Equity Shares of Rs. 10/- each fully paid up.	Sunday, September 4, 2022 to Saturday, September 10, 2022 (both days inclusive)	Annual General Meeting of the Company to be held on Saturday, September 10, 2022

Request you to Kindly take the same on your record.

Thanking you,

Yours Faithfully,  
For Aspira Pathlab & Diagnostics Limited



Priya Pandey  
Company Secretary & Compliance Officer

